Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid-and long-term prediction of hepatocellular carcinoma among cirrhotic patients

BACKGROUND The combination of alpha-fetoprotein(AFP)and squamous cell carcinoma antigen immunocomplex(SCCA-IgM)have been proposed for its use in the screening of hepatocellular carcinoma(HCC).Current screening programs for all cirrhotic patients are controversial and a personalized screening is an unmet need in the precision medicine era.AIM To determine the role of the combination of SCCA-IgM and AFP in predicting mid-and long-term appearance of HCC.METHODS Two-hundred and three cirrhotic patients(Child A 74.9%,B 21.2%,C 3.9%)were followed-up prospectively every six months to screen HCC by ultrasound and AFP according to European Association for the Study of the Liver guidelines.The estimation cohort was recruited in Italy(30.5%;62/203)and validation cohort from Spain(69.5%;141/203).Patients underwent to evaluate SCCA-IgM by enzyme-linked immunosorbent assay(Hepa-IC,Xeptagen,Italy)and AFP levels at baseline.Patients were followed-up for 60 mo,being censored at the time of the appearance of HCC.RESULTS There were 10.8%and 23.1%of HCC development at two-and five-years followup.Patients with HCC showed higher levels of SCCA-IgM than those without it(425.72±568.33 AU/mL vs 195.93±188.40 AU/mL,P=0.009)during the fiveyear follow-up.In multivariate analysis,after adjusting by age,sex,aspartate transaminase and Child-Pugh,the following factors were independently associated with HCC:SCCA-IgM[Hazard ratio(HR)=1.001,95%CI:1.000-1.002;P=0.003],AFP(HR=1.028,95%CI:1.009-1.046;P=0.003)and creatinine(HR=1.56495%CI:1.151-2.124;P=0.004).The log-rank test of the combination resulted in 7.488(P=0.024)in estimation cohort and 11.061(P=0.004)in the validation cohort,and a 100%of correctly classified rate identifying a low-risk group in both cohorts in the two-year follow-up.CONCLUSION We have constructed a predictive model based on the combination of SCCA-IgM and AFP that provides a new HCC screening method,which could be followed by tailored HCC surveillance for individual patients,especially for those cirrhotic patients belonging to the subgroup identified as low-risk of HCC development.

Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C

Hepatitis C virus(HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma(HCC), one of the most common fatal cancers worldwide- fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M(SCCA-Ig M), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-Ig M may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology.

High expression of squamous cell carcinoma antigen in poorly differentiated adenocarcinoma of the stomach: A case report

BACKGROUND Squamous cell carcinoma antigen(SCCA)is regarded as a specific indicator of epithelial malignancies and is widely used in the diagnosis of squamous cell carcinoma(SCC).However,the expression of SCCA in gastric adenocarcinoma has not been studied in detail.CASE SUMMARY A 52-year-old man was admitted to our hospital for a 2.5 cm x 2.5 cm ulcer at the antrum-body junction with dull pain and fullness in the upper abdomen for 2 mo.His pre-surgery serological testing results showed 0.51 ng/mL SCCA(reference interval,<1.5 ng/mL)and 9.9 ng/mL carcinoembryonic antigen(reference range,<4.7 ng/mL).He underwent radical distal gastrectomy and Roux-en Y anastomosis and was diagnosed with poorly differentiated mucinous adenocarcinoma(Lauren classification:Diffuse)by pathological examination of the resected lesion.Immunohistochemistry showed that SCCA was highly expressed in the cytoplasm of cancer cells.After surgery,the patient received an S-1 adjuvant chemotherapy regimen for six cycles containing tegafur,gimeracil,and oteracil potassium.He showed no sign of recurrence or metastasis within 24-mo follow-up.CONCLUSION This is a frontal report of SCCA overexpression in poorly differentiated adenocarcinoma of the stomach.

The serum squamous cell carcinoma antigen level in inverted sinonasal papilloma and nasal polyps patients

Objective:To clarify whether the serum squamous cell carcinoma antigen(SCCA)levels of patients with inverted papilloma(IP)are different from patients with nasal polyps(NP)and rhinitis.Materials and methods:Serum SCCA levels were measured in 30 patients with IP and 30 patients with NP at one day before surgery and seven days after surgery and measured in 28 patients with rhinitis.Results:Elevated serum SCCA levels(>1.5 ng/ml)were found in 80.0%of patients in the IP group,6.7%of patients in the NP group and 14.3%of patients in the rhinitis group,which was a significant difference.The medians of serum SCCA levels in the IP,NP and rhinitis groups were 3.9,0.8 and 1.1 ng/ml,respectively,which was a significant difference.The SCCA level in IP group was not significantly correlated according to Krouse Staging.There was a significant difference in serum SCCA levels between the pre-and postoperative stages in the IP group,at 3.9 and 0.8 ng/ml,respectively,while in the NP group the levels were 0.8 and 1.0 ng/ml,not significantly different.With regard to the IP diagnosis in the IP and NP group based on the SCCA level(>1.5 ng/ml),sensitivity and specificity was 80.0%and 93.3%,respectively.Conclusions:The serum SCCA level in patients with IP was elevated and then it decreased after surgery.This was different from NP and rhinitis patients who mostly had normal levels,which did not change.

Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma

Background Patients with esophageal squamous cell carcinoma （ESCC） undergoing definitive chemoradiotherapy （CRT） seem to have a disparity in therapeutic response. The identification of CRT sensitivity-related clinicopathological factors would be helpful for selecting patients most likely to benefit from CRT. Cytokeratin 19 fragment antigen 21-1 （CYFRA21-1） and carcinoembryonic antigen （CEA） have been reported as useful tumor markers for esophageal cancer. The aim of this study was to examine the predictive value of CYFRA21-1 in comparison with CEA and other clinicopathological factors in patients with ESCC treated with definitive CRT. Methods Pretreatment serum CYFRA21-1 and CEA levels were measured by immunoradiometric assays. The relationships between pretreatment clinicopathological factors and the efficacy of CRT were analyzed. Overall survival （OS） was estimated by univariate and multivariate analysis. Results The results from a univariate analysis indicated that the efficacy of CRT was significantly associated with the serum levels of CYFRA21-1 and CEA before treatment （P=0.001 and P=0.023, respectively）. It also indicated that the efficacy of CRT was significantly associated with the pretreatment tumor location （P=-0.041）. By Logistic regression analysis, the independent predictive factor associated with efficacy of CRT was CYFRA21-1 （P=0.002）. The OS of the patients with high CYFRA 21-1 levels was worse than that of those with low CYFRA21-1 levels （P=0.001）. In multivariate analysis, a low level of CYFRA21-1 was the most significant independent predictor of good OS （P=0.007）. Conclusions CEA and tumor location may be useful in predicting the sensitivity of ESCC to CRT. CYFRA21-1 may be an independent predictor for definitive CRT sensitivity in ESCC.

Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.

Serum Folate, MTHFR C677T Polymorphism and Esophageal Squamous Cell Carcinoma Risk

This study examined associations between MTHFR C677T polymorphism and serum folate concentrations with the risk of esophageal precancerous lesions （EPL） and esophageal squamous cell carcinoma （ESCC）. The highest quartile of serum folate concentration significantly decreased the risk of ESCC compared with the lowest quartile （0R=0.11; 95% CI, 0.04-0.33; P〈0.05）. MTHFR 677 C〉T polymorphism was associated with the risk of ESCC by using chi-square tests （P〈0.05）. For the CT genotype, the risk of ESCC significantly increased in study participants with low serum folate concentrations （〈26.92μg/L） compared with participants with high serum folate concentrations （〉26.92 μg/L） by using multinomial logistic regression models. The MTHFR genotype may further modify associations between serum folate concentrations and the risk of ESCC, but it was not significantly associated with the risk of EPL.

High level of preoperative serum fibrinogen is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma

Objective This study aimed to elucidate the association between the level of preoperative serum fibrinogen(PSF)and the prognosis of patients with esophageal squamous cell carcinoma(ESCC).Methods From January 2010 to December 2016,all patients diagnosed with ESCC who underwent surgery in Qingdao Municipal Hospital were analyzed retrospectively.Moreover,the fibrinogen levels of all patients were assessed before surgery,and hyperfibrinogenemia was diagnosed when the fibrinogen level was≥4.0 g/L.The impact of PSF on disease-free survival(DFS)and overall survival(OS)was analyzed using the log-rank method and Cox proportional hazards regression model.P value less than 0.05 was considered statistically significant.Results A total of 336 patients were finally analyzed,and approximately 102 patients(30.36%)were diagnosed with hyperfibrinogenemia before surgery.Hyperfibrinogenemia was associated with older age(≥70 years)(P=0.012),advanced pathological T stage(P=0.003),and lymph node involvement(P=0.024).Univariate analysis showed that patients with hyperfibrinogenemia had shorter DFS(1.96 years vs.3.64 years,P=0.001)and OS(2.27 years vs.4.15 years,P<0.001)than patients without hyperfibrinogenemia.Multivariate analysis confirmed that PSF was an independent factor affecting DFS(risk ratio[RR]:1.35,95%confidence interval[CI]:1.02-1.79,P=0.038)and OS(RR:1.37,95%CI:1.03-1.83,P=0.034)in patients with ESCC.Conclusion For patients with operable ESCC,hyperfibrinogenemia had poor prognosis.Moreover,PSF is an independent prognostic factor for operable ESCC.

Salivary and Serum IgA Evaluation of Patients with Oro-Facial Squamous Cell Carcinoma

Objective: To evaluate salivary and serum levels of Immunoglobulin A (IgA) in patients with oro-facial squamous cell carcinoma. Methods: This is a cross sectional study. Patients with oro-facial squamous cell carcinoma attending the Oral Pathology and Radiotherapy clinics of the University College Hospital, Ibadan, Nigeria were included. Seventy subjects comprising 22 patients with untreated OSCC, 18 patients with OSCC receiving treatment and 30 healthy, age and gender matched individuals were included. Serum and salivary samples from the participants were analysed for IgA levels using ELISA technique. Results: The mean value of serum IgA in OSCC patients receiving treatment was significantly lower compared with healthy controls (p = 0.03), while no significant difference was observed comparing untreated OSCC patients with treated and healthy controls. The salivary IgA levels did not show any significant difference between the three groups (p = 0.73). Also, there was no correlation between serum and salivary levels of IgA among the subjects. Conclusions: Serum IgA appeared to be better index than salivary IgA levels in monitoring response to treatment in patients with oro-facial carcinoma.

Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers

Objective: To determine if an amniotic fluid (AF)-specific marker is present and if its concentration changes with the presence of labor. Study Design: Twenty-six healthy women who gave birth to healthy newborns at term during the period from July 2009 to January 2010 were included in the study. Six candidate markers were assessed by commercially available ELISA kits: interleukin (IL)-6, squamous cell carcinoma (SCC) antigen, insulin-like growth factor (IGFBP)-1, osteopontin (OPN), CA125, and sialyl Tn (STN). Results: The AF/maternal serum (MS) measurement based on IL-6 or SCC has proved to be superior to IGFBP-1, CA125, OPN and STN. Women with spontaneous labor at term had significantly higher IL-6 and IGFBP-1 concentrations in AF compared with those without labor. No significant differences were observed in the AF concentrations of SCC, OPN, CA125 and STN between women with labor and those not in labor. Conclusion: Our observation of IL-6 and SCC in AF may open a new area of research to assess their usefulness as biological markers of obstetrical disorders.

Ciliated hepatic foregut cyst with high intra-cystic carbohydrate antigen 19-9 level

A ciliated hepatic foregut cyst(CHFC)is a rare foregut developmental malformation usually diagnosed in adulthood.Five percent of reported cases of CHFC transform into squamous cell carcinoma.We report the presentation,evaluation,and surgical management of a symptomatic 45-year-old male found to have a 6.2 cm CHFC.Contrast tomography-guided fine-needle aspirationdemonstrated columnar,ciliated epithelium consistent with the histologic diagnosis of CHFC.The intracystic levels of carbohydrate antigen(CA)19-9 and carcinoembryonic antigen(CEA)were extremely high(978118U/m L and 973μg/L,respectively).Histologically,the wall of the cyst showed characteristic pseudopapillae lined with a ciliated stratified columnar epithelium,underlying smooth muscle,an outer fibrous layer and no atypia.Immunohistochemistry for CA19-9 and CEA was positive.This is the first case report of a CHFC in which levels of CA 19-9 and CEA were measured.Our findings suggest that a large sized multilocular cyst and elevated cyst CA19-9 and CEA levels do not exclude a CHFC from consideration in the diagnosis.CHFCs should be included in the differential diagnosis of hepatic lesions.Accurate diagnosis of a CHFC is necessary given its potential for malignant transformation,and surgical excision is recommended.

Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma

AIM: To evaluate the diagnostic values of serum autoantibodies against matrix metalloproteinase-7 (MMP-7) in patients with esophageal squamous cell carcinoma (ESCC). METHODS: The MMP-7 cDNA was cloned from ESCC tissues, and MMP-7 was expressed and purified from a prokaryotic system. MMP-7 autoantibodies were then measured in sera from 50 patients with primary ESCC and 58 risk-matched controls, using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which autoantibodies to MMP-7 bound to the purified MMP-7 proteins. In addition, MMP-7 autoantibody levels in sera from 38 gastric cancer patients and from control serum samples were also tested. RESULTS: The optimum conditions for recombinant MMP-7 protein expression were determined as 0.04 mmol/L Isopropyl-β-D-Thiogalactopyranoside (IPTG) induction at 37℃ for four hours. The levels of serum autoantibodies against MMP-7 were significantly higher in patients with ESCC than in the matched-control samples (OD450 = 1.69 ± 0.08 vs OD450 = 1.55 ± 0.10, P < 0.001). The area under the receiver operating characteristic (ROC) curve was 0.87. The sensitivity and specificity for detection of ESCC were 78.0% and 81.0%, respectively, when the OD450 value was greater than 1.65. Although the levels of autoantibodies against MMP-7 were also significantly higher in patients with gastric cancer compared to control samples (OD450 = 1.62 ± 0.06 vs OD450 = 1.55 ± 0.10, P < 0.001), the diagnostic accuracy was less significant than in ESCC patients. The area of ROC curve was 0.75, whereas the sensitivity and specificity were 60.5% and 71.7%, respectively, when the cut-off value of OD450 was set at 1.60. CONCLUSION: Serum autoantibody levels of MMP-7 may be a good diagnostic biomarker for esophageal squamous cell carcinoma.

宫颈癌患者血清SCC-Ag、NLR水平与临床病理特征及预后关系

目的:探讨宫颈癌患者血清鳞状细胞癌抗原(SCC-Ag)、中性粒细胞与淋巴细胞比值(NLR)与临床病理特征及预后关系。方法:纳入2018年1月-2023年1月本院收治的108例宫颈癌患者为宫颈癌组,宫颈上皮内瘤病变(CIN)患者108例为CIN组,健康体检健康女性108例为对照组。比较3组血清SCC-Ag、NLR水平,分析宫颈癌组血清SCC-Ag、NLR水平与临床病理特征及与预后关系。结果:血清SCC-Ag、NLR水平,宫颈癌组(7.35±1.76、4.65±1.06)、CIN组(2.06±0.53、3.41±0.89)、对照组(0.54±0.12、1.53±0.34)依次降低(P<0.05)。宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级、肌层浸润深度和盆腔淋巴结转移有关(P<0.05)。Kaplan-Meier显示,SCC-Ag、NLR高表达组总生存率、无病生存率均低于SCC-Ag、NLR低表达组,SCC-Ag高表达+NLR高表达组总生存率、无病生存率最低(均P<0.05)。结论:宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级和肌层浸润深度等有关,且SCC-Ag、NLR水平越高患者预后越差。

血清SCC-Ag、HE4、SMAD4水平与宫颈癌放化疗敏感性的相关性分析

目的分析血清鳞状细胞癌相关抗原(SCC-Ag)、人附睾分泌蛋白4(HE4)、SMAD4水平与宫颈癌放化疗敏感性的相关性。方法选取接受放化疗治疗的宫颈癌患者74例为研究对象,根据放化疗敏感性分为抵抗组和敏感组,分别有48例和26例。检测患者治疗前后血清SCC-Ag、HE4及SMAD4 mRNA水平,分析治疗前血清SCC-Ag、HE4、SMAD4水平与超声参数的相关性。绘制受试者工作特征曲线(ROC)描述治疗前SCC-Ag、HE4及SMAD4 mRNA水平对放化疗敏感性的预测价值。结果治疗后2组患者血清SCC-Ag、HE4水平较治疗前降低,SMAD4 mRNA水平较治疗前升高(P<0.05);且敏感组患者治疗前、后SCC-Ag、HE4水平均低于抵抗组,SMAD4 mRNA水平均高于抵抗组(P<0.05)。治疗前血清SCC-Ag、HE4与VI呈正相关(γ=0.518、0.544,P<0.05),SMAD4 mRNA与VI呈负相关(γ=-0.581,P<0.05)。ROC曲线显示,治疗前SCC-Ag、HE4及SMAD4 mRNA联合对放化疗敏感性的预测价值较高,AUC为0.863(95%CI:0.764~0.962)。结论血清SCC-Ag、HE4及SMAD4 mRNA水平与宫颈癌放化疗敏感性密切相关,且三者联合对放化疗敏感性具有较高的预测价值。

HPV-DNA联合SCC-Ag、CA19-9、AFP检测诊断宫颈癌的临床价值

目的:分析人乳头瘤病毒DNA(HPV-DNA)联合鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)及甲胎蛋白(AFP)检测在宫颈癌诊断中的临床价值。方法:回顾性收集2018年3月-2022年3月本院诊治的宫颈癌患者、宫颈良性病变患者各80例临床资料,分别纳入宫颈癌组、良性病变组,同期健康体检女性50例纳入对照组,比较3组以及宫颈癌组不同FIGO分期患者血清SCC-Ag、CA19-9、AFP表达水平及HPV-DNA、SCC-Ag、CA19-9、AFP阳性率,以病理诊断为“金标准”,评价HPV-DNA、SCC-Ag、CA19-9、AFP单独及联合检测对宫颈癌的诊断效能。结果:宫颈癌组血清SCC-Ag、CA19-9、AFP表达水平均高于良性病变组与对照组,HPV-DNA、SCC-Ag、CA19-9、AFP阳性率均高于良性病变组与对照组,且宫颈癌组Ⅲ~Ⅳ期患者血清SCC-Ag、CA19-9、AFP表达水平均高于Ⅰ~Ⅱ期患者,HPV-DNA、CA19-9、AFP阳性率均高于Ⅰ~Ⅱ期患者(均P<0.05);HPV-DNA、SCC-Ag、CA19-9、AFP联合检测诊断宫颈癌的敏感度(96.3%)、准确度(91.8%)均高于各项单独检测,AFP诊断特异度最高达100.0%(P<0.05)。结论:HPV-DNA联合SCC-Ag、CA19-9、AFP检测可提高宫颈癌的诊断效能。

血清HE4、SCC-Ag联合TCT检查诊断宫颈癌价值

目的:探讨血清人附睾上皮分泌蛋白4(HE4)、鳞状细胞癌相关抗原(SCC-Ag)联合宫颈薄层液基细胞学检测(TCT)诊断宫颈癌(CC)价值。方法:收集2021年10月-2023年7月本院病理确诊CC患者40例(CC组)、宫颈良性病变(CBL组,包括宫颈炎、宫颈上皮内瘤变)患者228例为CBL组。对比两组血清HE4、SCC-Ag水平,两组HE4、SCC-Ag、TCT检测CL阳性检出率;根据病理结果分析血清HE4、SCC-Ag水平、TCT诊断CL价值。结果:CC组血清HE4(188.71±39.15 pmol/L)、SCC-Ag(1.81±0.21 ng/ml)水平高于CBL组(73.65±11.52 pmol/L、0.64±0.12 ng/ml)(P<0.05)。TCT、HE4、SCC-Ag诊断CC的灵敏度(82.5%、72.5%、75.0%),特异度(77.6%、87.7%、86.8%),准确度(78.4%、85.5%、85.1%),3项指标联合诊断CC的灵敏度70.0%、特异度93.9%、准确度90.3%,联合检测准确度高于各单独指标检测(P<0.05)。结论:CC患者血清HE4、SCC-Ag水平及TCT检测阳性率均高于CBL患者,3项指标联合诊断准确度提高。

激素替代疗法改善宫颈鳞癌术后患者更年期综合征的有效性和安全性及对其血清SCC-Ag、MMP-9的影响

目的探讨激素替代疗法(HRT)改善宫颈鳞癌术后患者更年期综合征的有效性和安全性及对其血清肿瘤标志物鳞状细胞癌抗原(SCC-Ag)、基质金属蛋白酶-9(MMP-9)的影响。方法回顾性选取2018年4月至2022年5月在保定市第一中心医院行手术治疗的86例宫颈鳞癌患者作为研究对象,按术后治疗方案的不同,分为对照组(n=41)与研究组(n=45)。对照组采用谷维素片口服,1~3片/次,3次/d。研究组采用戊酸雌二醇片口服,1片/次,1次/d,2组疗程均24周。比较两组围绝经期症状Kupperma评分、同时检测性激素[雌二醇、卵泡刺激素(FSH)、黄体生成素(LH)]水平与血清SCC-Ag、MMP-9水平及不良反应发生情况。结果治疗后24周,研究组围绝经期症状Kupperma评分低于治疗前,差异有统计学意义(P<0.05),而对照组治疗前后比较,差异无统计学意义(P>0.05);研究组治疗后围绝经期症状Kupperma评分为(14.52±4.55)分,低于对照组[(19.77±4.96)分],差异有统计学意义(P<0.05)。治疗后24周,研究组的雌二醇水平较治疗前升高,FSH、LH水平较治疗前降低,差异均有统计学意义(P<0.05),而对照组治疗前后比较,差异均无统计学意义(P>0.05);治疗后24周,研究组的雌二醇水平为(39.28±7.39)ng/L,高于对照组[(15.91±5.27)ng/L],FSH、LH水平分别为(34.18±7.59)、(20.29±6.02)U/L,均低于对照组[(58.72±13.16)、(32.93±6.25)U/L],差异均有统计学意义(P<0.05)。同组治疗前后、治疗后组间的血清SCC-Ag、MMP-9水平比较,各种不良反应发生率组间比较,差异均无统计学意义(P>0.05)。结论宫颈鳞癌术后HRT治疗能有效改善低雌激素引起的更年期综合征,调节性激素水平,且不影响血清SCC-Ag、MMP-9水平,未增加不良反应发生,安全性较好。

GPR120、SCC-Ag、PD-1在非小细胞肺癌中的表达及其与临床特征、预后的关系

目的:探究G蛋白耦联受体120(GPR120)、鳞状细胞癌抗原(SCC-Ag)、程序性死亡受体1(PD-1)在非小细胞肺癌中的表达及其与临床特征、预后的关系。方法:选取2018年1月1日—2019年12月31日新疆生产建设兵团第一师医院收治的经手术治疗的81例非小细胞肺癌患者。分析所有患者临床特征(性别、年龄、肿瘤直径、分化程度、临床分期、淋巴结转移、累及程度)及预后情况,检查所有患者癌组织、癌旁组织GPR120 mRNA、SCC-Ag、PD-1 mRNA。比较所有患者癌组织、癌旁组织GPR120 mRNA、SCC-Ag、PD-1 mRNA。比较不同临床特征患者癌组织GPR120 mRNA、SCC-Ag、PD-1mRNA。比较存活组及死亡组GPR120 mRNA、SCC-Ag、PD-1 mRNA。分析GPR120 mRNA与SCC-Ag、PD-1 mRNA的关系。分析GPR120 mRNA、SCC-Ag、PD-1 mRNA对患者预后的预测价值。结果:癌组织中的GPR120 mRNA、SCC-Ag、PD-1m RNA均高于癌旁组织,差异有统计学意义(P<0.05)。低分化、Ⅲ~Ⅳ期、有淋巴结转移、累计肌层患者癌组织GPR120m RNA、SCC-Ag、PD-1 mRNA均高于中高分化、Ⅰ~Ⅱ期、无淋巴结转移、未累计肌层患者,差异有统计学意义(P<0.05)。81例患者随访6个月,22例死亡,59例存活。死亡组GPR120 mRNA、SCC-Ag、PD-1 mRNA均明显高于存活组,差异有统计学意义(P<0.05)。Pearson结果显示,GPR120 mRNA与SCC-Ag呈正相关(r=0.368,P=0.001);GPR120 mRNA与PD-1 mRNA呈正相关(r=0.314,P=0.004);SCC-Ag与PD-1 mRNA呈正相关(r=0.295,P=0.007)。ROC曲线分析,三项联合诊断AUC值高于GPR120 mRNA、SCC-Ag、PD-1 mRNA单项诊断。结论:在非小细胞肺癌中GPR120、SCC-Ag、PD-1m RNA呈高表达状态,与患者分化程度、临床分期、淋巴结转移、累及程度相关,且与患者预后相关,三项联合检测对非小细胞肺癌患者预后存活、死亡的判断价值较高。

喉癌组织中FBXW7、SCC-Ag表达与临床病理参数及预后的关系

目的探讨喉癌组织中F框/WD-40域蛋白7(FBXW7)、鳞状细胞癌抗原(SCC-Ag)表达与临床病理参数及预后的关系。方法回顾性分析83例喉癌患者资料,比较患者癌组织及癌旁组织FBXW7、SCC-Ag表达阳性率;分析FBXW7、SCC-Ag表达与患者临床病理参数的关系;比较不同预后患者FBXW7、SCC-Ag表达的阳性率。结果患者癌组织FBXW7表达阳性率为22.89%,低于癌旁组织的90.36%;癌组织SCC-Ag表达阳性率为72.29%,高于癌旁组织的20.48%(P<0.05)。单因素分析显示,癌肿病理分期、分化程度、淋巴结转移情况与喉癌组织中FBXW7、SCC-Ag表达具有密切联系(P<0.05);随访6个月内预后良好患者癌组织FBXW7表达阳性率(29.63%)高于预后不良患者(10.34%),癌组织SCC-Ag表达阳性率(62.96%)低于预后不良患者(89.66%)(P<0.05)。结论喉癌组织中FBXW7表达阳性率明显降低,SCC-Ag阳性表达率显著升高。喉癌患者癌肿病理分期、分化程度、淋巴结转移情况均与其癌组织FBXW7、SCC-Ag表达关系密切,且癌组织FBXW7、SCC-Ag表达对患者预后情况有一定的提示作用。

血清SCC-Ag、VEGF、UHRF1水平联合预测食管鳞癌根治术后复发的价值

目的探讨血清人鳞状细胞癌相关抗原(SCC-Ag)、血管内皮生长因子(VEGF)、环指域1(UHRF1)水平联合预测食管鳞癌根治术后复发的价值。方法回顾性分析2017年5月至2019年6月因食管鳞癌于郑州大学第一附属医院接受根治术治疗的116例患者的临床资料。术前均检测血清SCC-Ag、VEGF、UHRF1水平,比较不同临床病理特征患者各血清指标。术后均随访3 a,根据是否复发将患者分为复发组(56例)和未复发组(60例),并比较两组血清SCC-Ag、VEGF、UHRF1水平和临床病理特征。采用Cox回归模型分析食管鳞癌根治术后复发的危险因素,并绘制受试者工作特征(ROC)曲线分析血清SCC-Ag、VEGF、UHRF1水平联合对食管鳞癌根治术后复发的预测价值。结果最大肿瘤直径>5 cm、有淋巴结转移、TNM分期Ⅲ期、低分化程度患者血清SCC-Ag、VEGF、UHRF1水平均高于最大肿瘤直径≤5 cm、无淋巴结转移、TNM分期Ⅰ~Ⅱ期、高/中分化程度患者(P<0.05);复发组血清SCC-Ag、VEGF、UHRF1水平和最大肿瘤直径>5 cm、有淋巴结转移、TNM分期Ⅲ期、低分化程度占比均高于未复发组(P<0.05);Cox回归模型分析结果显示,在未校正因素时,血清SCC-Ag、VEGF、UHRF1水平均是食管鳞癌患者根治术后3 a内复发的危险因素(RR=2.978、3.031、3.126,P<0.05),校正性别、年龄、肿瘤部位、最大肿瘤直径、淋巴结转移、TNM分期、分化程度后仍是术后3 a内复发的危险因素(RR=1.939、2.112、2.235,P<0.05);ROC曲线分析结果显示,血清SCC-Ag、VEGF、UHRF1水平联合预测食管鳞癌根治术后复发的灵敏度和曲线下面积(AUC)分别为94.64%、0.919,均高于各指标单独预测(P<0.05),其特异度与各指标单独预测比较差异无统计学意义(P>0.05)。结论血清SCC-Ag、VEGF、UHRF1水平与食管鳞癌患者临床病理特征和术后复发均具有一定的相关性,对术后复发均具有预测价值,但三者联合预测价值更高。